Valneva SE

Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
  • TickerVLS
  • ISINFR0004056851
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alexandre Iatrides ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 05/02/2019

...

Martial Descoutures ...
  • Pierre Corby

Valneva : Tight rein on costs

>Well above forecasts - This morning, Valneva reported its Q1 2019 results which came in well above forecasts. In short, sales were € 32.8m vs € 31.9m forecast (+9% at constant forex), for EBITDA of € 8.2m vs € 3.2m forecast (+67%), corresponding to a 25% of sales. On the back of this publication, the French biotech confirmed its guidance for 2019, i.e. sales growth of between +15% and 20% at constant forex leading to sales of € 115m-€ 125m. Group EBITDA is still anti...

Martial Descoutures ...
  • Pierre Corby

Valneva : Un bon contrôle des coûts

>Nettement au-dessus aux attentes - Valneva publie ce matin ses résultats du T1 2019 qui se révèlent nettement au-dessus des attentes. Brièvement le CA atteint 32.8 M€ vs 31.9 M€ att (+9% à tcc), pour un EBITDA de 8.2 M€ vs 3.2 M€ att (+67%) correspondant à un ratio de 25% sur les ventes. Suite à cette publication, la biotech française confirme sa guidance 2019 à savoir une hausse de son CA comprise entre +15% et +20% à tcc conduisant à des ventes de 115 M€ à 125 M€. ...

Alexandre Iatrides ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2019

...

Martial Descoutures ...
  • Pierre Corby

Valneva : Tight rein on costs

>Well above forecasts - This morning, Valneva reported its Q1 2019 results which came in well above forecasts. In short, sales were € 32.8m vs € 31.9m forecast (+9% at constant forex), for EBITDA of € 8.2m vs € 3.2m forecast (+67%), corresponding to a 25% of sales. On the back of this publication, the French biotech confirmed its guidance for 2019, i.e. sales growth of between +15% and 20% at constant forex leading to sales of € 115m-€ 125m. Group EBITDA is still anti...

Martial Descoutures ...
  • Pierre Corby

Valneva : Un bon contrôle des coûts

>Nettement au-dessus aux attentes - Valneva publie ce matin ses résultats du T1 2019 qui se révèlent nettement au-dessus des attentes. Brièvement le CA atteint 32.8 M€ vs 31.9 M€ att (+9% à tcc), pour un EBITDA de 8.2 M€ vs 3.2 M€ att (+67%) correspondant à un ratio de 25% sur les ventes. Suite à cette publication, la biotech française confirme sa guidance 2019 à savoir une hausse de son CA comprise entre +15% et +20% à tcc conduisant à des ventes de 115 M€ à 125 M€. ...

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Martial Descoutures ...
  • Pierre Corby

Valneva : A unique specialty vaccine, but well priced in by the market

Valneva is a French biotech group that specialises in developing vaccines, two of which are already being marketed. Sales for its two vaccines will likely have exceeded € 100m in 2018. Moreover, its clinical pipeline regroups three vaccines including the only existing one in the world against Lyme disease (in phase 2). We are initiating coverage on the stock with a Neutral recommendation and target price of € 4.2 per share. The market values the company at its fair value, in our ...

Alexandre Iatrides ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 05/02/2019

...

Alexandre Iatrides ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2019

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Etude de l'AG du 29/06/2017

Nous alertons l'entreprise sur le manque d'indépendance de son conseil de surveillance. En effet, seulement 30% des membres du conseil sont considérés comme libres de conflits d'intérêt selon Proxinvest, tandis que la société estime que son conseil est indépendant à au moins 50%. La société devrait davantages suivre les recommandations de son code de gouvernance afin de juger de l'indépendance de son conseil avec plus de justesse. La rémunération des dirigeants pose également problème sur plusieurs points : des problèmes de structure (augmentation non justifiée du fixe, rémunération actionnar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch